A Comprehensive Report on the Investigational Anti-TSLP Monoclonal Antibody: Bosakitug

Executive Summary

Bosakitug is an investigational, humanized monoclonal antibody representing a potentially significant advancement in the treatment of a broad spectrum of immuno-inflammatory diseases. As a high-affinity inhibitor of thymic stromal lymphopoietin (TSLP), Bosakitug targets a master regulator cytokine positioned at the apex of the Type 2 inflammatory cascade. This upstream mechanism of action provides a strong biological rationale for its development across multiple atopic, respiratory, and immunologic disorders. The compound is being co-developed under a geographically segmented global strategy by Aclaris Therapeutics (worldwide, excluding Greater China) and Chia Tai Tianqing Pharmaceutical Group (Greater China), having been originated by Biosion, Inc.

The most compelling evidence for Bosakitug's therapeutic potential comes from the Phase 2a ADAMANT proof-of-concept study in patients with moderate-to-severe atopic dermatitis. In this trial, Bosakitug demonstrated an exceptionally high degree of efficacy, with the vast majority of patients achieving clear or almost clear skin and profound improvements in eczema severity. These results, combined with a highly favorable safety and tolerability profile characterized by the absence of serious adverse events or anti-drug antibody formation, position Bosakitug as a formidable competitor to existing biologics, including the market leader dupilumab.

Preclinical and molecular characterization studies further distinguish Bosakitug, suggesting it possesses superior pharmacological properties compared to the first-in-class approved anti-TSLP agent, tezepelumab. These properties include very high potency, an extremely long residence time on its target, and enhanced neutralization activity. Clinically, these attributes appear to translate into a durable therapeutic effect that persists long after treatment cessation, supporting the potential for an extended, more convenient dosing interval.

With late-stage clinical development underway for severe asthma and chronic rhinosinusitis with nasal polyps in China, and a pivotal global Phase 2b trial initiated for atopic dermatitis, Bosakitug is poised at a critical juncture. The collective evidence strongly supports its potential to emerge as a best-in-class TSLP inhibitor and a cornerstone therapy for diseases driven by Type 2 inflammation. Future validation in larger, randomized, controlled trials will be crucial in confirming this promise.

Molecular Profile and Development History

The molecular identity and development pathway of Bosakitug reflect a sophisticated, globally coordinated strategy to advance a promising new biologic. A thorough understanding of its nomenclature, structure, and corporate stewardship is essential to appreciating its current status and future potential.

Nomenclature and Classification

Bosakitug is a protein-based therapeutic classified as a humanized immunoglobulin G1 kappa (IgG1κ) monoclonal antibody.[1] Its origin is a humanized mouse, a standard methodology for reducing the immunogenicity of murine-derived antibodies for human therapeutic use.[2] As a novel therapeutic agent, it is recognized as a

New Molecular Entity.[3] To date, it has not been granted Orphan Drug Status by any regulatory body.[3]

The compound is identified by several synonyms, each corresponding to a specific developer or stage in its lifecycle, which together map its strategic, geographically segmented development model.

• BSI-045B: The original designation from its originator, Biosion, Inc..[3]
• ATI-045: The designation used by Aclaris Therapeutics, which holds the development and commercialization rights for all territories excluding Greater China.[5]
• TQC-2731: The designation used by Chia Tai Tianqing Pharmaceutical Group (CTTQ), the development and commercialization partner for Greater China.[1]

This tripartite naming convention is not merely a list of alternative names but a direct reflection of a parallel development strategy. This structure allows for simultaneous late-stage clinical trials to be conducted in different major regulatory jurisdictions, leveraging regional expertise and potentially accelerating the overall timeline to global market access.

Structural and Physicochemical Characteristics

Bosakitug is a large protein molecule with a precisely defined structure. Its molecular weight is approximately 145.507 kDa.[1] The compound is registered under the Chemical Abstracts Service (CAS) number

2762183-23-1 and has been assigned the FDA Unique Ingredient Identifier (UNII) 5T953J9HZN, which facilitates its tracking across regulatory and scientific databases.[1]

The antibody is composed of four polypeptide chains: two identical heavy chains, each 447 amino acids in length, and two identical light chains, each 214 amino acids in length.[2] The complete amino acid sequences for these subunits have been publicly disclosed, a significant marker of its advanced and transparent development status. The publication of such detailed structural information indicates that the molecule is well-characterized and has likely surpassed key Chemistry, Manufacturing, and Controls (CMC) milestones required by regulatory agencies. This level of transparency signals a high degree of confidence from the developers and facilitates further academic investigation into its properties.

Corporate Development and Licensing Landscape

The development of Bosakitug is managed through a collaborative partnership between three key biopharmaceutical companies.

• Originator: Biosion, Inc., a global clinical-stage biotechnology company, discovered and conducted the initial development of the antibody.[3]
• Developers:
• Aclaris Therapeutics, Inc. acquired exclusive worldwide rights for the development and commercialization of Bosakitug (as ATI-045), with the specific exclusion of Greater China. This was part of a transformative licensing agreement that underscored the high perceived value of the asset.[3]
• Chia Tai Tianqing Pharmaceutical Group (CTTQ) is Biosion's partner responsible for the clinical development and commercialization of Bosakitug (as TQC-2731) within Greater China, where it is advancing the molecule in late-stage trials.[3]

This strategic division of territories allows for a focused and potentially accelerated path to market in distinct key regions, with CTTQ's efforts in China complementing the global program led by Aclaris.

Table 1: Bosakitug Drug Profile Summary

Attribute	Description	Source(s)
Generic Name	Bosakitug	5
Alternative Names	ATI-045, BSI-045B, TQC-2731, Anti-TSLP mAb	3
Drug Class	Anti-inflammatories, Antiallergics, Antiasthmatics, Monoclonal antibodies, Skin disorder therapies	3
Molecular Type	Humanized IgG1κ Monoclonal Antibody	1
Originator	Biosion, Inc.	3
Developers	Aclaris Therapeutics, Biosion, Chia Tai Tianqing Pharmaceutical Group	3
Mechanism of Action	Thymic stromal lymphopoietin (TSLP) inhibitor	3
CAS Number	2762183-23-1	1
Molecular Weight	~145.507 kDa	1
New Molecular Entity	Yes	3

Pharmacological Profile: Mechanism of Action and Rationale for TSLP Inhibition

The therapeutic rationale for Bosakitug is firmly rooted in its ability to potently and specifically neutralize thymic stromal lymphopoietin (TSLP), a cytokine that plays a central, upstream role in initiating and perpetuating allergic and inflammatory responses.

The Pivotal Role of TSLP in Immuno-Inflammatory Disease

TSLP is an epithelial cell-derived cytokine that functions as an "alarmin"—a molecule released by barrier tissues such as the skin, lungs, and gastrointestinal tract in response to inflammatory triggers, allergens, or pathogens.[6] Its expression is known to be significantly elevated in individuals with atopic and respiratory diseases, establishing it as a validated therapeutic target.[7]

TSLP is considered a master regulator at the apex of the Type 2 (Th2) inflammatory cascade.[7] Upon its release, TSLP exerts a profound influence on the immune system through several mechanisms:

• It activates and polarizes dendritic cells, instructing them to drive the differentiation of naive T cells into Th2 helper cells.[6]
• It directly promotes the proliferation of T-cells and enhances their production of Th2-associated cytokines.[6]
• It supports the expansion and differentiation of B-cells.[6]

By occupying this key upstream position, TSLP orchestrates the release of a broad array of downstream pro-inflammatory cytokines that are the direct effectors of tissue damage and symptoms in allergic diseases. These include interleukin-4 (IL−4), interleukin-5 (IL−5), interleukin-13 (IL−13), and interleukin-17 (IL−17), as well as other inflammatory mediators like the chemokine CCL17.[7]

This upstream mechanism provides a fundamental pharmacological advantage. Whereas many existing biologic therapies target individual downstream branches of the inflammatory cascade (e.g., anti-IL-5 therapies for eosinophilic asthma or anti-IL-4Rα for atopic dermatitis), a TSLP inhibitor acts as a single-molecule "master switch." By neutralizing TSLP, Bosakitug has the potential to simultaneously suppress multiple, distinct inflammatory pathways. This provides a compelling scientific rationale for its broad-spectrum efficacy across a variety of atopic, immunologic, and respiratory diseases and may explain the remarkably high response rates observed in complex conditions like atopic dermatitis.

Bosakitug's Molecular Mechanism of Action

Bosakitug functions as a potent TSLP inhibitor. Its mechanism of action is direct and specific: it binds to human TSLP with very high affinity, thereby physically blocking the cytokine from interacting with its heterodimeric receptor complex.[6] This steric hindrance effectively

disrupts TSLP-mediated signal transduction, preventing the initiation of the downstream inflammatory cascade.[6] The ultimate consequence of this action is the prevention of pro-inflammatory cytokine release from the wide range of immune cells that are targeted by TSLP, leading to a broad anti-inflammatory effect.[6]

Differentiating Pharmacodynamic Properties and "Best-in-Class" Rationale

While another TSLP inhibitor, tezepelumab, is already approved, Bosakitug is being developed with the objective of establishing a "best-in-class" profile. This claim is supported by several key differentiating pharmacodynamic properties that have been consistently highlighted by its developers.

• Superior Potency: Bosakitug is characterized by very high potency. Preclinical data from Biosion suggests it possesses an in vitro efficacy that is 200-fold higher than that of tezepelumab.[4]
• High Affinity and Long Residence Time: The antibody exhibits an extremely low dissociation rate from TSLP. This means that once Bosakitug binds to its target, the drug-target complex is highly stable and long-lasting. This property translates to a long residence time, a critical pharmacodynamic parameter that can be more predictive of in vivo activity than binding affinity alone.[6] A long residence time ensures a prolonged and durable blockade of the TSLP pathway, allowing the antibody to effectively neutralize and clear TSLP from deep tissue spaces.[12] This molecular property is the likely basis for the sustained clinical responses observed in trials even after dosing has ceased.
• Enhanced Neutralization Activity: The combination of high affinity and long residence time results in an overall enhanced neutralization activity, ensuring a comprehensive shutdown of TSLP signaling.[7]

These superior binding characteristics provide a strong foundation for the hypothesis that Bosakitug may achieve a greater depth of clinical response, a more durable effect, and a more convenient dosing schedule than existing therapies.

Clinical Development and Efficacy Analysis by Indication

Bosakitug is being systematically evaluated in a robust clinical development program targeting several high-value indications where TSLP-mediated inflammation is a key driver of disease pathology. The program is advancing rapidly, with parallel development tracks in North America and China.

Table 2: Clinical Development Pipeline for Bosakitug

Indication	Highest Development Phase (Global ex-China)	Highest Development Phase (China)	Key Clinical Trial(s)	Source(s)
Atopic Dermatitis	Phase II	Phase II	ADAMANT (Phase 2a, NCT05932654); Global Phase 2b (NCT07011706)	3
Severe Asthma	Preclinical/Phase II Data Pending	Phase III	NCT06829784	3
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)	Preclinical/Phase II Data Pending	Phase III	NCT07107256	3
Chronic Obstructive Pulmonary Disease (COPD)	Phase II	N/A	Not specified	3

Atopic Dermatitis (AD)

The most mature and compelling clinical data for Bosakitug comes from its development in moderate-to-severe atopic dermatitis, a chronic inflammatory skin disease affecting over 200 million people worldwide.[7]

Phase 2a ADAMANT Proof-of-Concept Trial

The ADAMANT study (NCT05932654) was a single-arm, open-label trial that enrolled 22 patients with moderate-to-severe AD.[5] The study's design was a strategic choice to facilitate informal comparisons with the market-leading biologic, dupilumab. Patients received a 300 mg subcutaneous (SC) dose of Bosakitug weekly for four weeks as an induction phase, followed by a 300 mg SC dose every two weeks through week 23.[17] This dosing regimen was deliberately selected to mimic that of dupilumab, allowing the developers to present the single-arm data in a context that enables powerful cross-trial comparisons without the cost and time of a formal head-to-head study at this stage.[17]

The efficacy results from this trial were exceptionally strong, demonstrating rapid, deep, and durable clinical responses.

Table 3: Summary of Efficacy Results from the ADAMANT (Phase 2a) Trial in Atopic Dermatitis

Efficacy Endpoint	Timepoint	Result (% of Patients Achieving Endpoint)	Source(s)
IGA score of 0 or 1 (Clear or Almost Clear Skin)	Week 23	79%	17
	Week 25	94%	12
EASI-75 (≥75% improvement in EASI score)	Week 23	89%	17
	Week 26	94%	7
EASI-90 (≥90% improvement in EASI score)	Week 23	44%	17
	Week 25	69%	12
EASI-100 (100% improvement in EASI score)	Week 23	28%	17
	Week 25	25%	12
Change in PP-NRS (Peak Pruritus)	End of Dosing	Mean decrease of ~3 points from baseline	17

Note: Minor variations in percentages and timepoints across sources likely reflect different data cuts presented at various scientific meetings or in press releases.

These efficacy rates, particularly for the high-bar endpoints of IGA 0/1 and EASI-90, are striking for a monotherapy and appear numerically superior to historical data from the pivotal trials of other approved biologics.

A profound finding from the study was the durability of the clinical response. Efficacy was observed to continue improving even after the final dose was administered, with subjects who had been off-treatment for eight weeks (at week 31) exhibiting a mean EASI score reduction of 93% from baseline.[17] In a remarkable case, one subject who discontinued treatment after seven doses due to pregnancy maintained an 82% EASI response six months after her last dose.[17] This is not merely a reflection of a long pharmacokinetic half-life but suggests a deep and lasting modulation of the underlying disease process, providing the strongest clinical evidence yet for the unique pharmacodynamic properties of Bosakitug and its potential for an extended dosing interval.

Phase 2b Global Trial

Building on these robust results, Aclaris Therapeutics initiated a global, randomized, double-blind, placebo-controlled Phase 2 trial (NCT07011706) on June 2, 2025.[7] This study is designed to enroll approximately 90 patients with moderate-to-severe AD to formally evaluate the efficacy and safety of Bosakitug against a placebo control.[7] The primary endpoint is the percent change from baseline in the Eczema Area and Severity Index (EASI) at week 24.[7] Top-line results from this pivotal trial are anticipated in the

second half of 2026 and represent a critical upcoming catalyst for the program.[7]

Severe Asthma

Bosakitug is in late-stage development for severe asthma, an indication where TSLP has been validated as a key therapeutic target.

• Development Status: The program for asthma is most advanced in China, where CTTQ is conducting a Phase III multicenter, randomized, double-blind, placebo-controlled trial (NCT06829784) in patients with poorly controlled severe asthma.[3]
• Efficacy Data: While specific clinical trial results for Bosakitug in asthma have not yet been released, Aclaris has announced plans to present Phase 2 asthma data in the first half of 2025.[4] The performance of the approved anti-TSLP mAb, tezepelumab, in severe asthma sets a high benchmark, with real-world studies showing it reduces the mean annualized exacerbation rate from 3.1 to 0.8 at one year and significantly improves symptom control.[22]

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

TSLP is also implicated in the pathophysiology of CRSwNP, making it another logical indication for Bosakitug.

• Development Status: Similar to asthma, the CRSwNP program is in Phase III in China.[3] CTTQ plans to initiate a Phase III trial (NCT07107256) with an estimated start date of September 2025.[3]
• Efficacy Data: No specific results for Bosakitug are available. However, the successful Phase III WAYPOINT trial for tezepelumab, which demonstrated a significant reduction in nasal polyp size and congestion, validates TSLP as a target in this disease and suggests a high probability of success for Bosakitug.[24]

Chronic Obstructive Pulmonary Disease (COPD)

Bosakitug is also being explored in COPD, with development reported to be in Phase II.[3] No further details regarding trial design or status are currently available.

Safety, Tolerability, and Pharmacokinetic Profile

The clinical data available to date indicate that Bosakitug possesses a highly favorable safety and pharmacokinetic profile, which is crucial for a therapeutic intended for chronic use in non-life-threatening, though highly burdensome, inflammatory diseases.

Clinical Safety and Tolerability Assessment

The most detailed safety data comes from the Phase 2a ADAMANT trial in 22 patients with atopic dermatitis, which demonstrated excellent tolerability over the course of the study.[17] The safety profile appears remarkably benign, dominated by local administration-related effects, which suggests a highly targeted mechanism of action with minimal off-target systemic toxicity.

Table 4: Summary of Safety and Tolerability from the ADAMANT (Phase 2a) Trial

Safety Parameter	Finding	Source(s)
Serious Adverse Events (SAEs)	None reported	17
Adverse Events (AEs)	19 AEs in 9 subjects; all Grade 1 (mild) except one Grade 2 (moderate) vertigo	17
Most Common AE (Local)	Injection site reactions (reported by 16 subjects)	17
Most Common AE (Systemic)	Headache (4 cases in 4 subjects)	17
Anti-Drug Antibodies (ADA)	None of the 22 subjects exhibited a positive ADA response	17

The complete absence of an ADA response in this initial patient cohort is a highly significant and positive finding. Immunogenicity is a major risk for biologic therapies, as the development of ADAs can lead to a loss of efficacy over time or mediate hypersensitivity reactions. A 0% ADA rate is a strong signal that the antibody's humanization was successful and that the molecule has a low intrinsic risk of being recognized as foreign by the patient's immune system. This substantially de-risks the long-term development program and is a key attribute for regulatory review and physician adoption.

Pharmacokinetic (PK) Profile and Dosing Implications

Pharmacokinetic samples collected during the ADAMANT study confirmed that Bosakitug has a long half-life, leading to sustained drug concentrations in the body.[17] This was clinically corroborated by the observation of maintained drug exposure and continued efficacy in a patient six months after treatment was discontinued.[17]

This favorable PK profile, combined with the molecular properties of long target residence time and the clinical observation of durable efficacy, provides a robust rationale for exploring extended dosing intervals in future clinical trials.[7] The ability to offer a less frequent administration schedule (e.g., quarterly) compared to established therapies (which typically require dosing every two to four weeks) would represent a significant clinical and commercial advantage, improving patient convenience and adherence.

Strategic Analysis and Competitive Landscape

Bosakitug is entering a competitive but rapidly growing market for biologics in immuno-inflammatory diseases. Its strategic positioning is defined by its potential to be not only a "fast follower" to the first-in-class TSLP inhibitor but a "best-in-class" agent with a superior profile that could challenge the current standards of care.

Comparative Analysis vs. Key Competitors

Bosakitug's competitive potential must be assessed against two key benchmarks: tezepelumab, the other TSLP inhibitor, and dupilumab, the market-leading biologic for atopic dermatitis.

Table 5: Competitive Landscape of Biologics in Atopic and Respiratory Diseases

Drug Name	Target / Mechanism	Key Differentiator vs. Bosakitug	Dosing Frequency (Approved/Potential)
Bosakitug	TSLP Inhibitor	Potentially superior potency, efficacy, durability, and less frequent dosing	Potential for extended interval (e.g., quarterly)
Tezepelumab	TSLP Inhibitor	First-in-class TSLP inhibitor; Bosakitug has 200x higher in vitro potency and longer residence time	Every 4 weeks
Dupilumab	IL-4Rα Inhibitor (blocks IL-4 & IL-13)	Downstream target; Bosakitug's ADAMANT data appears numerically superior in AD	Every 2 weeks

• Versus Tezepelumab (Anti-TSLP): Bosakitug is positioned as a direct, second-generation improvement. The differentiation is built on its molecular engineering, with developers consistently highlighting its superior potency, higher affinity, and longer residence time.[7] The claim of 200-fold higher in vitro efficacy is a key preclinical differentiator.[4] If these molecular advantages translate to superior clinical outcomes or a more convenient dosing regimen in head-to-head or comparative studies, Bosakitug could capture a significant share of the TSLP inhibitor market.
• Versus Dupilumab (Anti-IL-4Rα): In atopic dermatitis, dupilumab is the dominant commercial player. The impressive efficacy data from the ADAMANT trial, where response rates for IGA 0/1 (79-94%) and EASI-90 (44-69%) appear to exceed the benchmarks set in dupilumab's pivotal trials, provides a strong basis for a competitive challenge.[12] The conclusion drawn by the ADAMANT investigators—that Bosakitug's "substantially higher efficacy... underscore its competitiveness to dupilumab"—will be a central part of its value proposition.[17]

Advanced Development and Life-Cycle Management Strategy

Aclaris Therapeutics is executing a sophisticated strategy that extends beyond Bosakitug alone. The company has also licensed ATI-052, a next-generation, investigational bispecific antibody that targets both TSLP and the IL-4 receptor (IL-4R).[6] This molecule utilizes the

exact same TSLP-binding antigen-binding fragment (Fab) region as Bosakitug but adds a second, complementary mechanism of action by also blocking IL-4 and IL-13 signaling.[25] Furthermore, ATI-052 is engineered to bind more tightly to the neonatal Fc receptor (FcRn), a modification designed to further extend its half-life.[6]

This represents a clear and deliberate "pipeline-in-a-product" and life-cycle management strategy. Bosakitug (ATI-045) serves as the lead asset, aimed at establishing a market presence with a potentially best-in-class profile. ATI-052 is the follow-on product, designed to offer potentially enhanced efficacy through dual-pathway blockade, extend the intellectual property franchise, and defend against future competition. This dual-asset approach significantly strengthens Aclaris's long-term strategic position in the immunology market.

The Role of the CTTQ Partnership as a Strategic Accelerator

The parallel late-stage development of Bosakitug in China by CTTQ serves as a powerful de-risking and data-accelerating engine for Aclaris's global program. Aclaris has explicitly stated that data from CTTQ's Phase 2 studies in asthma and CRSwNP are expected to "inform internal development programs".[27] This arrangement allows Aclaris to gain crucial proof-of-concept data in two additional major indications without bearing the full financial and operational burden of conducting those trials itself. Positive data from the Chinese trials would provide immense confidence and a clear, data-driven roadmap for Aclaris to commit to its own global Phase III trials in these indications, significantly de-risking the substantial investment required and shortening the overall decision-making timeline.

Future Outlook and Concluding Remarks

Bosakitug has emerged as a highly promising investigational therapeutic with a compelling profile that supports its potential to become a best-in-class TSLP inhibitor and a leading treatment for a range of immuno-inflammatory diseases. Its upstream mechanism of action, superior molecular properties, outstanding early clinical efficacy in atopic dermatitis, and favorable safety profile provide a strong foundation for continued development.

The future trajectory of the Bosakitug program will be defined by several key upcoming catalysts:

• Top-line results from the global, randomized, placebo-controlled Phase 2b trial in atopic dermatitis (NCT07011706), expected in the second half of 2026. This is the most critical near-term value inflection point, as it will either validate or temper the exceptional findings from the open-label ADAMANT study.
• Results from CTTQ's Phase III trials in China for severe asthma (NCT06829784) and chronic rhinosinusitis with nasal polyps (NCT07107256). Positive outcomes from these studies will provide crucial late-stage validation of the drug's efficacy in respiratory indications and will inform Aclaris's global Phase III strategy.

In conclusion, the comprehensive body of evidence available to date strongly suggests that Bosakitug is a highly differentiated molecule. The primary remaining hurdle is the replication of its impressive early-stage findings in larger, well-controlled Phase III settings. Should these pivotal trials prove successful, Bosakitug has the potential to significantly impact the treatment landscape for millions of patients and become a major commercial asset in the global immunology market.

Works cited

1. Bosakitug (BSI-045B) | Anti-TSLP Antibody - MedchemExpress.com, accessed August 28, 2025, https://www.medchemexpress.com/bosakitug.html
2. BOSAKITUG - gsrs, accessed August 28, 2025, https://gsrs.ncats.nih.gov/ginas/app/ui/substances/412f7306-9e06-44a6-b12f-94e584c64175
3. Bosakitug - Aclaris Therapeutics/Biosion - AdisInsight - Springer, accessed August 28, 2025, https://adisinsight.springer.com/drugs/800066183
4. Bosakitug Drug Profile - Ozmosi, accessed August 28, 2025, https://pryzm.ozmosi.com/product/25037
5. Bosakitug: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 28, 2025, https://go.drugbank.com/drugs/DB19101
6. Investigational Drug Candidates | Aclaris Therapeutics Inc., accessed August 28, 2025, https://www.aclaristx.com/investigational-drug-candidates/
7. Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis, accessed August 28, 2025, https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-initiates-phase-2-trial-bosakitug-ati-045
8. Biosion Partner CTTQ Pharma Announces Phase II Trial of BSI-045B/TQC2731, a Novel anti-TSLP Antibody for Chronic Rhinosinusitis with Nasal Polyps, is Active and Recruiting Patients, accessed August 28, 2025, https://www.biosion.com/news/datail/6560460d3012ea6c586c8d76
9. Bosakitug - Inxight Drugs, accessed August 28, 2025, https://drugs.ncats.io/drug/5T953J9HZN
10. BOSAKITUG - gsrs, accessed August 28, 2025, https://gsrs.ncats.nih.gov/ginas/app/beta/substances/5T953J9HZN
11. Bosakitug - Inxight Drugs, accessed August 28, 2025, https://drugs.ncats.io/substance/5T953J9HZN
12. Biosion Today Presented Key Phase 2 POC Clinical Study Results for Bosakitug, an Anti-TSLP mAb, in Atopic Dermatitis Subjects at the Revolutionizing Atopic Dermatitis Conference - BioSpace, accessed August 28, 2025, https://www.biospace.com/biosion-today-presented-key-phase-2-poc-clinical-study-results-for-bosakitug-an-anti-tslp-mab-in-atopic-dermatitis-subjects-at-the-revolutionizing-atopic-dermatitis-conference
13. Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets, accessed August 28, 2025, https://www.biosion.com/news/datail/673b422228d661e81904926b
14. Pipeline - Biosion, accessed August 28, 2025, https://www.biosion.com/pipeline
15. Bosakitug - Drug Targets, Indications, Patents - Synapse, accessed August 28, 2025, https://synapse.patsnap.com/drug/cd97cfc0982c4dfd95c7173b5a6f9936
16. Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis, accessed August 28, 2025, https://www.globenewswire.com/news-release/2025/06/02/3091709/37216/en/Aclaris-Therapeutics-Initiates-Phase-2-Trial-of-Bosakitug-ATI-045-in-Atopic-Dermatitis.html
17. 717 - Clinical efficacy, safety, and pharmacokinetic profile of ..., accessed August 28, 2025, https://academic.oup.com/bjd/article-abstract/191/Supplement_2/ljae266.090/7728647
18. investor.aclaristx.com, accessed August 28, 2025, https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-initiates-phase-2-trial-bosakitug-ati-045#:~:text=Bosakitug%20is%20an%20investigational%20humanized,complex%20and%20disrupting%20signal%20transduction.
19. AD Pipeline Watch: Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug, accessed August 28, 2025, https://thedermdigest.com/ad-pipeline-watch-aclaris-therapeutics-initiates-phase-2-trial-of-bosakitug/
20. Aclaris Therapeutics Starts Phase 2 Trial of Bosakitug for Atopic Dermatitis, accessed August 28, 2025, https://synapse.patsnap.com/article/aclaris-therapeutics-starts-phase-2-trial-of-bosakitug-for-atopic-dermatitis
21. Shanghai Zhengda Tianqing Pharmaceutical Co., Ltd. - Drug, accessed August 28, 2025, https://synapse.patsnap.com/organization/8fcd4a513e6c92ef91fe60c56b4ecec4
22. Clinical and Biological Remission With Tezepelumab: The Real‐World Response in Severe Uncontrolled Asthma - PMC, accessed August 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12186586/
23. Study Details | Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps | ClinicalTrials.gov, accessed August 28, 2025, https://clinicaltrials.gov/study/NCT07107256?term=physio+OR+physical+therapy+OR+exercise+therapy+OR+physiotherapy
24. Tezspire met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps - AstraZeneca, accessed August 28, 2025, https://www.astrazeneca.com/media-centre/press-releases/2024/tezspire-nasal-polyps-trial-met-primary-endpoints.html
25. Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody, accessed August 28, 2025, https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-secures-us-food-and-drug-administration-ind
26. Biosion's Partner Aclaris Therapeutics Announces FDA Clearance of IND Application for ATI-052, a Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody 2025-04-27, accessed August 28, 2025, https://www.biosion.com/news/datail/680e1fb51392638bed0e0fe5
27. Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - BioSpace, accessed August 28, 2025, https://www.biospace.com/press-releases/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-a-corporate-update